Cat. No.: HY-B1715

Oxiracetam

(Synonyms: ISF2522)

1 Cited Publications

Customer Review

Based on 1 publication(s) in Google Scholar

Oxiracetam (ISF2522) is an orally active and a BBB-penetrable cyclic derivative of γ-aminobutyric acid (GABA). Oxiracetam reaches the hippocampus and cerebral cortex in high concentrations. Oxiracetam can promote cognitive function and regulate inflammatory response, with powerful neuroprotective effects. Oxiracetam can be used in the study of central nervous system diseases .

For research use only. We do not sell to patients.

Purity: 99.86%
CAS No.: 62613-82-5
Formula: C₆H₁₀N₂O₃
Molecular Weight:158.16

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

Oxiracetam Chemical Structure

CAS No.: 62613-82-5

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- Cellular Effect
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (1)
Solvent & Solubility
- In Vitro
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

All NO Synthase Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
Huh-7	CC₅₀	57.48 μM Compound: GNF-Pf-1005	NOVARTIS: Cytotoxicity against human hepatocellular carcinoma cell line (Huh7) NOVARTIS: Cytotoxicity against human hepatocellular carcinoma cell line (Huh7)	[PMID: 18579783]

In Vitro

Oxiracetam (100 μM; 12-24 h) inhibits Aβ-induced cell activation, inflammatory molecules expression and NO production in BV2 cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Real Time qPCR^[1]

Cell Line:

Aβ treated BV2 microglial cells
Concentration:

100 μM
Incubation Time:

12 h
Result:

Reduced the level of iNOS mRNA.

In Vivo

Oxiracetam (30 mg/kg; intraperitoneal injection; 4 weeks) improves cognitive impairment induced by chronic cerebral ischemia in rats^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Male adult Sprague-Dawley rats (220-240 g) with chronic cerebral hypoperfusion (CCH) model^[2]
Dosage:

30 mg/kg
Administration:

Intraperitoneal injection (i.p.)； 4 weeks
Result:

Prevented spatial learning and memory impairment induced by CCH.
Rescued the CCH-induced LTP decrease.
Prevented the white matter lesions of CA3 nerve fibres.
Maintained BDNF levels and CREB activity in rat brains.
Prevented CCH-induced deterioration of dendritic spines and synapses.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS No. 62613-82-5
Appearance Solid
Molecular Weight 158.16
Formula C₆H₁₀N₂O₃
Color White to off-white
SMILES

O=C(N)CN1C(CC(O)C1)=O
Synonyms

ISF2522
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (1)

All

Sort by:

Journal Impact Factor

J Nanobiotechnology

Biosynthesized nanoparticles of Tibetan medicine mercuric sulfide preparation to promote endocytosis and realize drug crossing through blood brain barrier. [Abstract]

2025 Jun 16;23(1):445. PMID: 40524151

Solvent & Solubility

In Vitro:

H₂O : ≥ 100 mg/mL (632.27 mM)

DMSO : 25 mg/mL (158.07 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

6.3227 mL

31.6136 mL

63.2271 mL

5 mM

1.2645 mL

6.3227 mL

12.6454 mL

10 mM

0.6323 mL

3.1614 mL

6.3227 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (274 KB)
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Zhang H, et al. Oxiracetam Offers Neuroprotection by Reducing Amyloid β-Induced Microglial Activation and Inflammation in Alzheimer's Disease. Front Neurol. 2020 Jul 17;11:623 [Content Brief]

[2]. Yao XL, et al. Oxiracetam can improve cognitive impairment after chronic cerebral hypoperfusion in rats. Psychiatry Res. 2016 Dec 30;246:284-292. [Content Brief]

[3]. Li W, et al. (S)-Oxiracetam is the Active Ingredient in Oxiracetam that Alleviates the Cognitive Impairment Induced by Chronic Cerebral Hypoperfusion in Rats. Sci Rep. 2017 Aug 30;7(1):10052. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO / H₂O	1 mM	6.3227 mL	31.6136 mL	63.2271 mL	158.0678 mL
	5 mM	1.2645 mL	6.3227 mL	12.6454 mL	31.6136 mL
	10 mM	0.6323 mL	3.1614 mL	6.3227 mL	15.8068 mL
	15 mM	0.4215 mL	2.1076 mL	4.2151 mL	10.5379 mL
	20 mM	0.3161 mL	1.5807 mL	3.1614 mL	7.9034 mL
	25 mM	0.2529 mL	1.2645 mL	2.5291 mL	6.3227 mL
	30 mM	0.2108 mL	1.0538 mL	2.1076 mL	5.2689 mL
	40 mM	0.1581 mL	0.7903 mL	1.5807 mL	3.9517 mL
	50 mM	0.1265 mL	0.6323 mL	1.2645 mL	3.1614 mL
	60 mM	0.1054 mL	0.5269 mL	1.0538 mL	2.6345 mL
	80 mM	0.0790 mL	0.3952 mL	0.7903 mL	1.9758 mL
	100 mM	0.0632 mL	0.3161 mL	0.6323 mL	1.5807 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Keywords

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Oxiracetam

Anti-COVID-19 Compound Library

NMPA-Approved Drug Library

Orally Active Compound Library

Neurotransmitter Receptor Compound Library

FDA Approved & Pharmacopeial Drug Library

Anti-Alzheimer's Disease Compound Library

Neuroprotective Compound Library

Anti-Parkinson's Disease Compound Library

Neurodegenerative Disease-related Compound Library

Angiogenesis-Related Compound Library

Antidepressant Compound Library

GABA Receptor Compound Library

Human Metabolite Library

Off-patent Drug Library

Mitochondrial Protection Compound Library

Metabolic Enzyme Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Ion Channel Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Anti-Infection Compound Library

Immunology/Inflammation Compound Library

Membrane Transporter/Ion Channel Compound Library

Neuronal Signaling Compound Library

FDA-Approved Drug Library

CNS-Penetrant Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

Publications Citing Use of MedChemExpress (MCE) Oxiracetam

All NO Synthase Isoforms

Biological Activity

Chemical Information

Publications (1)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Oxiracetam Related Classifications

HY-B1715 Related Classifications